Acuta Capital Partners LLC Has $1.66 Million Stock Holdings in Dyne Therapeutics, Inc. (NASDAQ:DYN)

Acuta Capital Partners LLC lowered its position in Dyne Therapeutics, Inc. (NASDAQ:DYN) by 78.3% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 46,200 shares of the company’s stock after selling 166,300 shares during the quarter. Dyne Therapeutics accounts for about 1.3% of Acuta Capital Partners LLC’s holdings, making the stock its 23rd largest position. Acuta Capital Partners LLC’s holdings in Dyne Therapeutics were worth $1,660,000 at the end of the most recent reporting period.

Other institutional investors also recently modified their holdings of the company. Seven Eight Capital LP increased its stake in Dyne Therapeutics by 195.7% in the second quarter. Seven Eight Capital LP now owns 53,739 shares of the company’s stock valued at $1,896,000 after acquiring an additional 35,568 shares during the period. State of New Jersey Common Pension Fund D bought a new stake in shares of Dyne Therapeutics in the 3rd quarter valued at approximately $1,588,000. Jennison Associates LLC grew its stake in shares of Dyne Therapeutics by 1.5% in the 3rd quarter. Jennison Associates LLC now owns 1,346,952 shares of the company’s stock valued at $48,383,000 after purchasing an additional 19,730 shares during the period. Mutual of America Capital Management LLC acquired a new position in shares of Dyne Therapeutics in the 2nd quarter worth approximately $1,724,000. Finally, Vanguard Group Inc. lifted its position in shares of Dyne Therapeutics by 47.7% during the 1st quarter. Vanguard Group Inc. now owns 3,440,270 shares of the company’s stock worth $97,669,000 after buying an additional 1,110,629 shares during the period. Institutional investors and hedge funds own 96.68% of the company’s stock.

Dyne Therapeutics Price Performance

Shares of Dyne Therapeutics stock opened at $31.13 on Thursday. The firm has a 50 day simple moving average of $31.95 and a 200 day simple moving average of $35.42. Dyne Therapeutics, Inc. has a fifty-two week low of $10.12 and a fifty-two week high of $47.45. The firm has a market cap of $3.17 billion, a P/E ratio of -8.15 and a beta of 1.10.

Dyne Therapeutics (NASDAQ:DYN) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.96) EPS for the quarter, missing analysts’ consensus estimates of ($0.71) by ($0.25). On average, sell-side analysts expect that Dyne Therapeutics, Inc. will post -3.45 EPS for the current year.

Analyst Upgrades and Downgrades

DYN has been the topic of a number of analyst reports. Guggenheim upped their price target on Dyne Therapeutics from $45.00 to $50.00 and gave the company a “buy” rating in a research report on Thursday, August 15th. Morgan Stanley increased their target price on shares of Dyne Therapeutics from $48.00 to $52.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 14th. Chardan Capital reissued a “buy” rating and set a $50.00 price target on shares of Dyne Therapeutics in a report on Wednesday, November 13th. Oppenheimer reaffirmed an “outperform” rating and set a $55.00 price objective on shares of Dyne Therapeutics in a research note on Tuesday, September 3rd. Finally, JPMorgan Chase & Co. cut shares of Dyne Therapeutics from an “overweight” rating to a “neutral” rating and cut their target price for the company from $43.00 to $35.00 in a research note on Thursday, October 24th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, nine have issued a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Dyne Therapeutics currently has an average rating of “Moderate Buy” and an average price target of $50.82.

Insider Buying and Selling

In related news, Director Dirk Kersten sold 79,411 shares of the stock in a transaction that occurred on Friday, September 20th. The shares were sold at an average price of $36.45, for a total value of $2,894,530.95. Following the transaction, the director now directly owns 234,127 shares in the company, valued at $8,533,929.15. This represents a 25.33 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Jason P. Rhodes sold 782 shares of Dyne Therapeutics stock in a transaction on Thursday, November 14th. The stock was sold at an average price of $33.10, for a total transaction of $25,884.20. Following the sale, the director now directly owns 15,962 shares of the company’s stock, valued at $528,342.20. This represents a 4.67 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 176,257 shares of company stock worth $6,193,718 over the last three months. 20.77% of the stock is currently owned by company insiders.

Dyne Therapeutics Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.